Diabetes Medications: SGLT2 Inhibitors and GLP-1 Agonists Reduce Alzheimer’s Risk by 43% and 33%
Recent clinical research indicates that patients with Type 2 diabetes treated with SGLT2 inhibitors may experience a significantly lower incidence of Alzheimer’s disease compared to those using other glucose-lowering medications. According to a large-scale study published in The BMJ, the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of dementia, suggesting … Read more